Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) Price Target at $175.67

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $175.6667.

A number of equities analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Piper Sandler raised their price target on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. KeyCorp upped their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lido Advisors LLC boosted its position in shares of ICU Medical by 4.5% during the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock valued at $354,000 after purchasing an additional 106 shares in the last quarter. CIBC Asset Management Inc acquired a new position in ICU Medical in the fourth quarter valued at approximately $225,000. Goldman Sachs Group Inc. boosted its holdings in shares of ICU Medical by 2.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 284,551 shares of the medical instruments supplier’s stock worth $40,597,000 after buying an additional 5,837 shares in the last quarter. Norges Bank acquired a new stake in shares of ICU Medical during the 4th quarter worth approximately $58,083,000. Finally, Baker Avenue Asset Management LP bought a new stake in shares of ICU Medical in the 4th quarter valued at $212,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $153.22 on Friday. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. ICU Medical has a twelve month low of $107.00 and a twelve month high of $165.17. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -494.24 and a beta of 0.79. The company’s fifty day moving average is $148.84 and its 200 day moving average is $134.83.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.